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ALS

:   amyotrophic lateral sclerosis

ALSFRS‐R

:   Amyotrophic Lateral Sclerosis Functional Rating Scale---Revised

COVID‐19

:   coronavirus disease 2019

FDA

:   US Food and Drug Administration

NEALS

:   Northeast Amyotrophic Lateral Sclerosis Consortium

1. INTRODUCTION {#mus26989-sec-0001}
===============

The coronavirus disease 2019 (COVID‐19) pandemic has created unprecedented challenges for neuromuscular clinicians and researchers working across several different diseases.[^1^](#mus26989-bib-0001){ref-type="ref"}, [^2^](#mus26989-bib-0002){ref-type="ref"}, [^3^](#mus26989-bib-0003){ref-type="ref"}, [^4^](#mus26989-bib-0004){ref-type="ref"}, [^5^](#mus26989-bib-0005){ref-type="ref"} The specific impact on amyotrophic lateral sclerosis (ALS) care and research is illustrated in a recent survey of members of the Northeast ALS (NEALS) Consortium, a network of ALS clinical centers. Most of the 133 sites surveyed between April 21, 2020 and May 1, 2020 are affiliated with academic medical centers in the United States, have multidisciplinary care teams, see large numbers of patients, and participate in a variety of ALS research studies, including clinical trials.[^6^](#mus26989-bib-0006){ref-type="ref"} The survey itself is included in Figure [S1](#mus26989-supitem-0001){ref-type="supplementary-material"} (see Supplementary Material online). Results from the 61 sites that responded are shown in Tables [1](#mus26989-tbl-0001){ref-type="table"}, [2](#mus26989-tbl-0002){ref-type="table"}, and [3](#mus26989-tbl-0003){ref-type="table"}.

###### 

Options for evaluation of new and return clinic patients at NEALS sites

                                       New patients: number offering (%)   Return patients: number offering (%)
  ------------------------------------ ----------------------------------- --------------------------------------
  In‐person                            41 (67%)                            32 (53%)
  Video (in any state)                 18 (29%)                            24 (56%)
  Video (in some but not all states)   14 (23%)                            19 (31%)
  Video (in my state)                  38 (62%)                            42 (69%)
  Phone                                25 (41%)                            52 (87%)
  Not able to offer                    2 (3%)                              0 (0%)

Abbreviation: NEALS, Northeast Amyotrophic Lateral Sclerosis.

###### 

Limitations on evidence‐ and experience‐based ALS care options at NEALS sites

  Option                             Sites reporting difficulty (%)
  ---------------------------------- --------------------------------
  Spirometry                         42 (69%)
  Feeding tubes                      21 (34%)
  Multiciplinary team care           20 (33%)
  Wheelchairs                        14 (23%)
  Home health/hospice                11 (18%)
  Ventilators                        6 (10%)
  Lifts                              6 (10%)
  Hospital beds                      1 (2%)
  None (can get everything I need)   10 (16%)

Abbreviations: ALS, amyotrophic laterial sclerosis; NEALS, Northeast Amyotrophic Lateral Sclerosis.

###### 

Options for research patients at NEALS sites

                                                              Number offering (%)
  ----------------------------------------------------------- ---------------------
  New enrollments in person                                   12 (20%)
  New enrollments by phone or video                           15(25%)
  Follow‐ups in person                                        24 (39%)
  Follow‐ups by phone or video (in any state)                 31 (51%)
  Follow‐ups by phone or video (in some but not all states)   11 (18%)
  Follow‐ups by phone or video (in my state)                  28 (46%)
  Unable to see any research patients                         13 (21%)

Abbreviation: NEALS, Northeast Amyotrophic Lateral Sclerosis.

###### 

COVID‐19 challenges and opportunities in ALS care and research

+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Challenges                                                                                                                                                                  | Opportunities                                                                                                                                                           |
+:============================================================================================================================================================================+:========================================================================================================================================================================+
| Inability to offer face‐to‐face clinic and research visits                                                                                                                  | • Capitalize on the large growth in telemedicine availability, at least for follow‐up clinic patients and research patients                                             |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Inability to perform spirometry, including vital capacity which is used as an inclusion criteria in trials, and to plan timing of several care options (eg, NIV initiation) | • Use home‐based spirometry                                                                                                                                             |
|                                                                                                                                                                             |                                                                                                                                                                         |
|                                                                                                                                                                             | • Develop alternative measures that correlate well with spirometry but are simpler and carry no increases risk of infection (eg, counting out loud, vocalizing a sound) |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Limited availability of several evidence‐ and experience‐based ALS care options                                                                                             | • Capitalize on previous work showing that multidisciplinary ALS care is possible via telemedicine                                                                      |
|                                                                                                                                                                             |                                                                                                                                                                         |
|                                                                                                                                                                             | • Account for variability in care options across different trial sites                                                                                                  |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------+

Abbreviations: ALS, amyotrophic laterial sclerosis; COVID‐19, coronavirus 2019; NIV, noninvasive ventilation.

2. IMPACT OF COVID‐19 ON ALS CLINICAL CARE AND RESEARCH {#mus26989-sec-0002}
=======================================================

The first two survey questions asked about available options for the clinical evaluation of new and return patients (Table [1](#mus26989-tbl-0001){ref-type="table"}). One third of responding centers were no longer able to see new patients in‐person. More than half of the responders were able to see new patients from their same state by video visit. Smaller numbers were able to offer video visits outside their state. Only 3% of responders were unable to see any new patients. With regard to follow‐up patients, again a large number of responders (47%) were unable to see these in‐person. Most could offer video visits to return patients in their same state, with smaller numbers being able see patients from other states. All responders were able to see follow‐up patients in some manner.

Question 3 asked about evidence‐ and experience‐based ALS measurements and treatments that may be challenging to obtain during the pandemic (Table [2](#mus26989-tbl-0002){ref-type="table"}). Spirometry was unavailable at most sites. Many sites reported difficulty getting feeding tubes, multidisciplinary team care, wheelchairs, home health/hospice, lifts, or hospital beds. Only 16% of responders reported being able to get everything they could for their patients before the pandemic.

Question 4 asked about available options for research participants (Table [3](#mus26989-tbl-0003){ref-type="table"}). Very few responding centers were able to enroll new participants into studies, either in‐person or by phone or video. Most were unable to see participants for return in‐person visits. About half the responders were able to see return participants virtually, even those residing in states beyond where the clinic was located. Twenty percent of responders were unable to see any research participants by any means during the pandemic.

3. CHALLENGES TO ALS CLINICAL CARE AND RESEARCH {#mus26989-sec-0003}
===============================================

Our survey results confirm that COVID‐19 has created specific challenges to ALS care and research in the United States. The first of these is making/confirming new ALS diagnoses. It is not clear how this may occur at sites that are now unable to offer in‐person visits. Current ALS diagnostic criteria require a physical examination showing widespread upper and lower motor neuron signs.[^7^](#mus26989-bib-0007){ref-type="ref"}, [^8^](#mus26989-bib-0008){ref-type="ref"} Although some aspects of a neurological examination can now be performed virtually, including measures of muscle bulk and power, assessment of muscle tone and tendon reflexes still cannot.[^9^](#mus26989-bib-0009){ref-type="ref"} This is likely to aggravate the already significant problem of diagnostic delay in ALS.[^10^](#mus26989-bib-0010){ref-type="ref"} Unfortunately, there may be no immediate way around it because previous work has shown that preliminary ALS diagnoses by nonexperts are inaccurate about 5% of the time.[^11^](#mus26989-bib-0011){ref-type="ref"} Even if a clinician could be certain of the findings documented by another provider, he or she may not feel comfortable breaking the news of an ALS diagnosis virtually. This idea is supported by a survey of clinicians showing they felt that telemedicine visits lacked the emotional connection associated with in‐person visits.[^12^](#mus26989-bib-0012){ref-type="ref"}

The second challenge relates to monitoring disease progression for clinical care and in trials. The most commonly used measure of ALS progression in clinics and in trials, the Amyotrophic Lateral Sclerosis Functional Rating Scale---Revised (ALSFRS‐R), can be obtained reliably and easily over the phone or by telemedicine.[^13^](#mus26989-bib-0013){ref-type="ref"} Unfortunately, another important measure, spirometry, has recently been unavailable at almost 70% of NEALS sites. Even when patients can be seen in‐person, use of spirometry has been cautioned by experts because it can stimulate a cough, which can aerosolize COVID‐19 droplets and thus create an increased risk of spread.[^14^](#mus26989-bib-0014){ref-type="ref"} Spirometry is one of the main ways ALS clinicians determine prognoses, and make decisions about when to offer various evidence‐based ALS care options, including noninvasive ventilation, invasive ventilation, feeding tubes, and hospice.[^15^](#mus26989-bib-0015){ref-type="ref"}, [^16^](#mus26989-bib-0016){ref-type="ref"} It is also a key inclusion criterion for most ALS trials. With the restrictions placed on in‐person visits at some sites, it is also not clear how key parts of safety monitoring in research participants such as blood draws and electrocardiograms can be performed.

A third challenge is the sudden unavailability of many key ALS treatment options. Multidisciplinary team care, which is associated with improved quality and length of life in people with ALS,[^17^](#mus26989-bib-0017){ref-type="ref"} is currently unavailable at one third of NEALS sites. Placement of feeding tubes, which are important for maintaining weight and improving survival in ALS patients[^18^](#mus26989-bib-0018){ref-type="ref"}; wheelchairs, which keep patients active and prevent falls; home health and hospice, which provide education as well as support and palliative care, are also all currently unavailable at some NEALS some sites. These restrictions can also affect research studies. It has largely been assumed that baseline ALS care being provided at different sites of a multicenter trial is similar; this assumption is currently incorrect.

4. OPPORTUNITIES FOR ALS CLINICAL CARE AND RESEARCH {#mus26989-sec-0004}
===================================================

The rapid expansion of telemedicine represents an exciting opportunity to improve clinical care and expand access to research opportunities for many patients (Table 4). At the beginning of 2020, a small but growing number of ALS centers were offering telemedicine visits to patients in their homes.[^12^](#mus26989-bib-0012){ref-type="ref"}, [^19^](#mus26989-bib-0019){ref-type="ref"}, [^20^](#mus26989-bib-0020){ref-type="ref"}, [^21^](#mus26989-bib-0021){ref-type="ref"} Because no billing codes existed for this, it was supported by philanthropy, ALS nonprofits, or local institutions. Many states had laws restricting telemedicine visits to clinicians licensed in that state.[^22^](#mus26989-bib-0022){ref-type="ref"} The current pandemic has catalyzed the creation of new billing codes for telemedicine in the home,[^23^](#mus26989-bib-0023){ref-type="ref"}, [^24^](#mus26989-bib-0024){ref-type="ref"} and many states have recently suspended their telemedicine licensure requirements.[^25^](#mus26989-bib-0025){ref-type="ref"} As evidenced by the NEALS survey, within a matter of weeks of the COVID‐19 pandemic in the United States, more ALS centers were offering telemedicine for established patients than were offering traditional in‐clinic visits. In medicine, where change is usually slow, the rapid acceptance and delivery of telemedicine is unprecedented. Although some patients still do not have internet access at home, that number is dwindling.[^26^](#mus26989-bib-0026){ref-type="ref"} In addition, hospital systems have invested in telemedicine teams to handle the massive increase in internet traffic to and from their institutions. Even as the COVID‐19 pandemic resolves, partnering with patient advocacy groups will help ensure that telemedicine remains an effective tool to allow clinicians more effective care for patients for whom travel to the clinic is burdensome, fatiguing, or otherwise impractical.

We should also expand upon this new telemedicine infrastructure. First, we should increase the number of sites that can use it to provide multidisciplinary team care. Such care is known to improve quality of life[^27^](#mus26989-bib-0027){ref-type="ref"} and survival[^28^](#mus26989-bib-0028){ref-type="ref"} for people with ALS. During an in‐person visit, the multidisciplinary providers generally see patients in succession while the patient remains in a single room for a multihour visit. Although this approach is still tenable for some teams using telemedicine,[^12^](#mus26989-bib-0012){ref-type="ref"} other approaches can also be successful. These can include hybrid models in which some clinicians see patients face‐to‐face and others see them virtually,[^29^](#mus26989-bib-0029){ref-type="ref"} models where the physician visit is scheduled and follow‐up visits with the multidisciplinary team occur ad hoc over time,[^19^](#mus26989-bib-0019){ref-type="ref"} and asynchronous visits using recorded video for patients without access to internet.[^17^](#mus26989-bib-0017){ref-type="ref"} In the Veterans Affairs hospital system, one analysis demonstrated that quality of ALS care was independent of its delivery by telemedicine or in clinic.[^20^](#mus26989-bib-0020){ref-type="ref"}

Some measurements or evaluations will need to be altered to be administered via telemedicine. Although spirometry is generally considered a clinic‐based assessment, it can also be done using a home spirometer and having a trained clinic staff monitor the patient as he/she performs the spirometry.[^30^](#mus26989-bib-0030){ref-type="ref"} Some home spirometers are approved by the US Food and Drug Administration (FDA) and web‐connected, transmitting data directly to a central database. Ultimately, these devices could transmit data directly into the electronic medical record. Preliminary studies in the national Answer ALS program suggest app‐based vital capacity can be monitored (unpublished observations).

Surrogates for spirometry could also be explored for ALS patients. These may include single‐breath counting or vocalizing a sound; these have proven to correlate with spirometry in other study populations.[^31^](#mus26989-bib-0031){ref-type="ref"}

When it comes to using telemedicine for research, remote or virtual consent platforms already exist. In fact, the FDA published a final guidance in December 2016 for institutional review boards, investigators, and sponsors.[^32^](#mus26989-bib-0032){ref-type="ref"} This can ease the hurdle of recruiting and enrolling people living with ALS into clinical trials. Another aspect of clinical trial design that can be improved is the frequency of in‐person visits. It may be possible to conduct remote or virtual visits, conducting home safety measures by sending a service to the home to collect labs or electrocardiograms. Novel research outcomes are emerging that can be obtained virtually. Digital voice recordings and quantitative speech analysis can be evaluated through recordings from cellphone apps to monitor disease progression.[^33^](#mus26989-bib-0033){ref-type="ref"} Medical surveys can be delivered to people with ALS, and quantitative data about movement can be collected. As algorithms for processing data mature, passive cell phone data could be used to inform providers about patient well‐being.[^34^](#mus26989-bib-0034){ref-type="ref"}, [^35^](#mus26989-bib-0035){ref-type="ref"} Wearables may paint an even more detailed picture of patient function and behavior, although with the cost of requiring the patient to wear an additional device.[^35^](#mus26989-bib-0035){ref-type="ref"}

5. DISCUSSION {#mus26989-sec-0005}
=============

The COVID‐19 pandemic has created an unprecedented challenges to ALS clinical care and research. The traditional face‐to‐face paradigm of medical decisionmaking and trial conduct have become difficult or impossible for many sites. An unexpected silver lining to these challenges is the development and maturation of a telemedicine infrastructure, providing clinicians and researchers with opportunities to fortify and even improve the way we approach ALS care and research. Our combined experiences of clinician‐patient interactions during this pandemic will provide us with new paradigms that will likely improve the efficiency of clinical care and availability of research participation.
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###### 

**Appendix** **S1**: Supplementary Material: NEALS COVID‐19 Survey

###### 

Click here for additional data file.
